Search
Temanogrel
go.drugbank.com/drugs/DB05227InvestigationalAPD791 is intended to lower the risk of arterial thrombosis by reducing the amplification of platelet aggregation, arterial constriction and intimal hyperplasia mediated by serotonin. … APD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena.
Lisinopril
go.drugbank.com/drugs/DB00722ApprovedInvestigational[A184853] It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system.
Diphenoxylate
go.drugbank.com/drugs/DB01081ApprovedIllicitInvestigationalThis medication is classified as a Schedule V under the Controlled Substances Act by the Food and Drug Administration (FDA) and the DEA in the United States when used in preparations.
Polydatin
go.drugbank.com/drugs/DB11263ApprovedIt is shown to mediate a cytotoxic action on colorectal cancer cells by inducing cell arrest and apoptosis [A27229].
Rice bran oil
go.drugbank.com/drugs/DB11293ApprovedInvestigationalRice bran oil is classified as an indirect additive used in food contact substances by the FDA.
Dactinomycin
go.drugbank.com/drugs/DB00970ApprovedInvestigationalA compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termina...
Corticosterone
go.drugbank.com/drugs/DB04652InvestigationalAn adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid.
Sirna-027
go.drugbank.com/drugs/DB05896InvestigationalSirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. It is used to treat Macular degeneration.
Oteseconazole
go.drugbank.com/drugs/DB13055ApprovedInvestigational[L41635] This drug was approved by the FDA on April 26, 2022.[L41645] … [L41635,A247020] By binding and inhibiting CYP51, oteseconazole is active against most microorganisms associated with recurrent vulvovaginal candidiasis (RVVC).
Ivosidenib
go.drugbank.com/drugs/DB14568ApprovedInvestigational[L46287] It was fully approved by the EMA in May 2023.[L46596] … [A248745] Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults.